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Abstract
Background: Despite the existence of efficacious vaccines, the burden of vaccine-preventable diseases remains
high and the potential health benefits of paediatric, adolescent and adult vaccination are not being achieved due
to suboptimal vaccine coverage rates.
Main body of abstract: Based on emerging evidence that pharmacy-based vaccine interventions are feasible and
effective, the European Interdisciplinary Council for Ageing (EICA) brought together stakeholders from the medical
and pharmacy professions, the pharmaceutical industry, patient/ageing organisations and health authorities to
consider the potential for pharmacy-based interventions to increase vaccine uptake. We report here the
proceedings of this 3-day meeting held in March 2018 in San Servolo island, Venice, Italy, focussing firstly on
examples from countries that have introduced pharmacy-based vaccination programmes, and secondly, listing the
barriers and solutions proposed by the discussion groups.
Conclusions: A range of barriers to vaccine uptake have been identified, affecting all target groups, and in various
countries and healthcare settings. Ease of accessibility is a potentially modifiable determinant in vaccine uptake, and
thus, improving the diversity of settings where vaccines can be provided to adults, for example by enabling
community pharmacists to vaccinate, may increase the number of available opportunities for vaccination.
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Introduction
The incidence of vaccine-preventable diseases has
decreased dramatically in recent decades. The incidence of
influenza (flu), pneumococcal disease and herpes zoster has
been substantially reduced thanks to vaccination [1, 2]. The
potential health benefits and cost savings that could be
yielded from vaccination are not being achieved due to
suboptimal vaccine coverage rates in most European
countries.
A range of barriers to vaccine uptake have been identi-
fied [3–6]. Ease of accessibility is a potentially modifiable
determinant, and thus, improving the diversity of
settings where vaccines can be provided to adults will
likely increase the number of available opportunities for
vaccination, thus improving vaccine-coverage rates [7].
One possible setting where adult vaccines can be given
is in the community pharmacy. The role played by com-
munity pharmacies varies widely around the world.
Pharmacies remain a privileged point of contact with the
public, and face challenges in managing patients and
providing optimum service, while also wrestling with
issues such as medication supply, storage, and handling.
Pharmacists are often the most frequently consulted
healthcare professional for many individuals, and are
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often consulted for healthcare advice. Clearly, the phar-
macist’s role is polyvalent, and their pharmacies are an
ideal point of contact with the potential to implement
positive healthcare initiatives. To fulfil the key role that
they could play in vaccination, it is important that phar-
macists are well informed about vaccine research and
development, product characteristics as well as manufac-
turing specificities and complexity.
Main text
In this context, the European Interdisciplinary Council
for Ageing (EICA) has an important role to play in
fostering interdisciplinary analyses, initiating high-level
discussions, as well as in translating and disseminating
the results of ageing research to various professional
groups, policy makers, and the general public. Based on
emerging evidence that pharmacy-based vaccine inter-
ventions are feasible and effective, the EICA sought to
bring together stakeholders from the medical and phar-
macy professions, the pharmaceutical industry, patient/
ageing organisations and health authorities to consider
the potential for pharmacy-based interventions to
increase vaccine uptake. To this end, a 3-day meeting
was organized from 14 to 16 March 2018, on San
Servolo Island, Venice, Italy, bringing together almost
100 international participants (75% from the public sec-
tor (pharmacies, professional societies, universities) and
25% from the private sector (pharmaceutical industry)).
We report here the proceedings of this meeting, focus-
sing firstly on examples from countries that have intro-
duced pharmacy-based vaccination programmes, and
secondly, listing the barriers and solutions proposed by
the discussion groups. This report supplements a recent
survey from the International Pharmaceutical Federation
of the activity of pharmacists as immunizers in multiple
countries [8].
Examples of countries that have introduced pharmacy-
based vaccine services
The Republic of Ireland
Ireland is an island nation situated on the western edge
of the European Union, with a population of around
4.76 million. As of early 2018, there were 3625 commu-
nity pharmacists working in 1849 community pharma-
cies [9], representing around 37.5 pharmacies per 100,
000 inhabitants, which is slightly higher than the OECD
average of 24.7/100,000 [10]. In 2008, the Pharmaceut-
ical Society of Ireland (PSI) published an interim report
on how the pharmacy profession could contribute to the
development of a more integrated approach to health-
care in Ireland in order to enhance services to patients.
The report concluded that pharmacists could make a
significant impact in critical areas of healthcare, for sev-
eral reasons. Firstly, pharmacies are the primary care
service with the greatest reach into the general popula-
tion, and their typically long opening hours provide ease
of accessibility. Secondly, pharmacists have the most
frequent contact with the population in Ireland. Thirdly,
the pharmacist is ideally placed to assess, identify, con-
tact and encourage at-risk individuals in the population
as a whole and initiate an intervention that would result
in vaccine uptake. With these factors in mind, the report
called for the development of a national policy and strat-
egy for maximising the use of vaccines, taking account
of the huge potential of the community pharmacy
network, to improve patient outcomes and take pressure
off other healthcare providers. It also called for the
development of national standards and protocols for the
delivery of vaccination and immunisation programmes
through community pharmacies in Ireland.
In 2011, a change to the legislation in Ireland intro-
duced new provisions allowing for pharmacist-led influ-
enza vaccination [11], expanding in 2015 to include
herpes zoster and pneumococcal vaccination [12]. The
PSI, the pharmacy regulator in Ireland, published guid-
ance on the provision of vaccination services by pharma-
cists in the retail pharmacy setting [13]. In partnership
with the Irish Institute of Pharmacy, the PSI developed a
modular system of training to equip pharmacists with
the necessary skills and knowledge to safely administer
medicines and vaccines to patients in the retail phar-
macy setting. Pharmacy-based vaccination was rolled out
starting with the seasonal influenza vaccination in the
2011/2012 season, when a total of 9125 vaccines were
delivered by pharmacists, rapidly increasing to almost
80,000 vaccines by the 2016/2017 season in Ireland. The
PSI conducts audits and inspections to ensure the ser-
vices are being delivered to the correct standards. In the
most recent evaluation of this service, patient satisfac-
tion with this service was high, with 95% of patients de-
claring that they were very satisfied with the information
received from the pharmacist about vaccination, and
93% rating overall flu service at 9 or 10 out of 10 [14].
This report noted that 47% of patients indicated that
their motivation for attending the pharmacy for the flu
vaccination was the convenience this service offered,
combined with the shorter waiting times (cited by 28%),
while cost was a motivating factor for only 13% of
patients, likely because many patients receive the vac-
cines for free under the national healthcare system [14].
Several challenges beset the path to pharmacy-based vac-
cination in Ireland, including storage requirements, difficul-
ties meeting vaccine delivery schedules, administrative
issues including funding and compatibility between data re-
cording systems, inter-professional communication, work-
load management and vaccine hesitancy among the public.
Once these barriers were overcome, and pharmacy-based
vaccination was successfully launched, progress was then
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made in expanding the portfolio of available vaccines, and
there is likely potential for further developments in the
future. Some adaptations may be necessary according to
the different vaccines proposed, for example due to differ-
ences in administration schedules. However, the overall
success of the Irish experience in introducing pharmacy-
based vaccination services underlines the feasibility of this
model of healthcare delivery, and can serve as a model for
other countries who are considering doing the same.
Canada
Canadians experience long wait times for access to
healthcare services [15] and this is a major public health
challenge. By diverting some of the care to pharmacies,
wait times can be significantly reduced. Public trust in
the community pharmacist is high in Canada, and phar-
macists have the competency and skills required to fully
embrace enhanced scope of practice. Since 2005, the
pharmacists’ scope of practice has been substantially ex-
panded in Canada, at varying rates across the different
provinces. With respect to vaccination, pharmacists are
authorized to inject flu vaccines, and in some provinces,
also other vaccines funded by public or private payers.
Reimbursement models vary by jurisdiction and are
major determinants for the successful implementation of
vaccination programmes. Many pharmacies are reluctant
to adopt these services in the absence of appropriate
funding. Flu and other public vaccines that are refunded
by the public health system are generally adopted on a
wide scale. Indeed, in 2016 in Canada, 2.2 million injec-
tions were given in pharmacies, of which 93% were flu
vaccines. As noted by patient feedback in the Republic
of Ireland, convenience and accessibility are major
drivers of success. Other advantages include cost savings
for the healthcare system, reduced physician workload
and wait times, and overall economic improvement. It is
noteworthy that the number of vaccines given is increas-
ing, but physician vaccination is not decreasing notice-
ably, which underlines the fact that pharmacy-based
vaccine services target different individuals who may not
be reached by the existing system via family doctors or
other primary care centres. This debunks the argument
that pharmacy-based vaccine services are in competition
with general practitioners (GPs) and primary care. In
addition, vaccination services provide an additional
source of revenue for pharmacists.
The body of evidence evaluating the impact of
pharmacy-based vaccination in Canada is growing. In a
study comparing estimated influenza vaccine coverage
before and after pharmacists began administering pub-
licly funded influenza immunizations in Nova Scotia,
Isenor et al. reported that in 2013–2014, the vaccination
coverage rate increased to 42%, up from 36% in 2012–
2013 (p < 0.001), and pharmacists administered over 78,
000 influenza vaccinations overall, corresponding to
nearly 9% of the province’s population over the age of
five [16]. Influenza vaccine coverage rates for those aged
65 years and older also increased by 9.8% (p < 0.001) in
2013–2014, compared to 2012–2013. By comparison,
pooled data from the 2007–2014 cycles of the Canadian
Community Health Survey (n = 481,526) showed that
the introduction of a policy for pharmacist administra-
tion of influenza vaccine was associated with a modest
increase in coverage (2.2%) and an individual’s likelihood
of uptake (adjusted prevalence ratio 1.05, 95% confi-
dence interval 1.02–1.08) [17]. Taken together, these
data provide robust evidence that pharmacy-based vac-
cination programmes improve vaccine uptake in the
community, and highlight again the feasibility of rolling
out such services, even in geographical areas as large as
Canada, despite differing regulations and rates of legisla-
tive change across the various provinces.
Contrasting evidence
In contrast to the Canadian experience, there has been
some conflicting evidence from the United Kingdom
(UK) regarding the usefulness of pharmacist vaccination.
Two studies evaluating community pharmacy based
vaccination services reported high patient satisfaction
and improved convenience, but no impact on vaccine
uptake and only weak evidence that the system widens
access to previously unvaccinated subjects [18, 19]. In an
online survey of London pharmacists delivering vaccines,
Atkins et al. reported that there was potential for
improved convenience, but no statistically significant
increase in uptake over the period studied, although
vaccine delivery in the pharmacy cost less than adminis-
tration by a GP [20]. These results should be interpreted
in light of the regulatory environment surrounding
pharmacy-based vaccine administration in the UK, with
the simultaneous use of two reporting systems to gather
data about vaccine delivery, as well as voluntary partici-
pation in the programmes. However, they do suggest
that programmes to introduced pharmacy-based vaccine
administration may not meet with the same success
everywhere, and will likely require adaptation to account
for local conditions, regulatory environment and pre-
existing services.
Strategies towards overcoming barriers
A wide range of barriers exist to increased vaccine
uptake via pharmacy-based interventions, including
regulatory, professional, personal (at the level of pharma-
cists individually and as a profession), and financial
obstacles. During our meeting, focus groups identified
the main barriers to the implementation of pharmacy-
based vaccine services, and proposed solutions for
overcoming them.
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Engage the profession
The first important strategy is to increase the involve-
ment of pharmacies in vaccine implementation by mo-
tivating pharmacists, as a profession, to engage in the
activity. They must come together as a single body to
voice their support and commitment to changing the so-
cial context of pharmacists vaccinating, with this new
service introduced, approved and widely used. This uni-
fied approach from the profession as a whole, repre-
sented by its professional organisations, guilds or other
bodies, will be necessary to provide the momentum and
political will to overcome the barriers, particularly a
need for a change to existing legislation.
Training
It is important to develop the necessary competence
within the profession to ensure that if the lobbying is suc-
cessful, then the pharmacists will be sufficient in number,
and adequately trained to implement the service and man-
age any complications. This calls for professional bodies
to define suitable learning objectives in line with the ser-
vices planned to be implemented. This includes but is not
limited to assessing the person’s vaccination status, advis-
ing on appropriate vaccinations considering the person’s
age and health status, prescribing and/or dispensing vac-
cines, administering vaccines, monitoring for complica-
tions, dealing with any emergency complications that may
occur, and notifying and reporting adverse events. Such
curricula have been developed by pharmacists in multiple
countries. Then, a training programme for the profession
must be developed, so that a pharmacist who has success-
fully completed the training can be considered to have the
skills and competences required to implement the planned
service. This may require endorsement from one or sev-
eral universities, or faculties, to deliver an academic dip-
loma commensurate with the level of training, thus giving
credence to the level of qualification. Nationwide rolling
out of the training must be implemented to ensure that all
pharmacies have at least one qualified individual available
to perform vaccination when the service becomes avail-
able to the public. Training and qualifications already exist
in a number of countries; in the United States of America,
for example, the American Pharmacists Association pro-
vides certified training that is now used in other regions as
well, and the International Pharmaceutical Federation
(FIP) offers this training to its members.
Advocacy and lobbying
Once the professionals are motivated as a single voice, and
have acquired the necessary skills, advocacy and lobbying
are the next steps. The regulatory situation of the country
must be assessed to identify which dispositions of the law
or regulation need to be changed or adapted, in terms of
the description of scope and the modalities of practice, to
allow the service to be implemented. This effort can often
proceed simultaneously with the previous two points. New
requirements may need to be laid down if no such services
were ever provided in pharmacies, in the interests of public
health, such as technical details on the ordering, storage
and dispensation of vaccine products, management of staff
and vaccination schedules, minimal facilities to ensure
patient privacy on the premises, etc. These requirements
need to be enshrined in the law and/or regulation, with
guidelines for practical implementation by the profession.
The discussions surrounding the exact modalities for
implementing vaccine strategies in pharmacies should
ideally take place in open dialogue with other healthcare
professionals and other interested stakeholders. The
objective is complementarity between healthcare profes-
sionals, for the benefit of the population, by improving
access to adult vaccination, thus expanding possibilities to
reach a broader audience and ensure wider availability of
vaccines for the public.
Internal regulatory diversity
In countries that have a federal governmental structure,
such as Canada or Switzerland, or other forms of
regional decentralization of healthcare provision, in-
ternal regulatory diversity is an added challenge, since
the laws or regulations then need to be changed in each
individual province, state or canton. In addition, the
scope given to pharmacists in terms of vaccination im-
plementation may differ between jurisdictional entities.
Nonetheless, evidence shows that when one or several
regions successfully initiate the service and collect evi-
dence in support of its efficacy, then through a domino
effect, the other regions often follow suit, as reported by
studies of the Canadian experience [16, 17] .
Generating evidence of efficacy
Generating evidence of the efficacy of pharmacy-based im-
plementation of vaccine strategies is important to maintain
motivation among the profession, and provide a rationale
that policy-makers can use to justify wider implementation.
Documenting is vital to establishing a precedent for other
regions within the same countries, or for other countries to
follow. To create such data, it is ideal to start with a small
group of motivated, engaged pharmacists, and work in col-
laboration with academics or other partners to assess im-
plementation and effectiveness using validated performance
measures. This will help to generate robust evidence of
expanding coverage, increased patient satisfaction, and
proof that pharmacy-based vaccination reaches new popu-
lations who now get a vaccine where they never did before,
as a result of improved access to vaccines. Evidence will
consolidate the service and support advocacy for third party
remuneration at a regional and national level, which is im-
portant for sustainability.
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Access to health records
Access to health records is an important element of
strategy, not only for vaccination but for most pharmacy
services in general to provide better service. It is essen-
tial to have access to reliable data about what vaccines
the patient already received, to enable the pharmacist to
advise appropriately, and take measures by providing
vaccination or referring the patient to another provider.
Self-reported vaccination history is not reliable enough
for pharmacists to administer vaccines on this basis
alone. However, in the absence of universal electronic
medical health records, the issue of medical data is
thorny. In particular, such questions as who hosts the in-
formation, who can view it, who can modify it (by add-
ing or deleting), and whether and how it can include
payment data, are dealt with differently, if at all, within
and between countries. Overall, an immunization regis-
try system that is complete, yet flexible enough for all
stakeholders involved (healthcare professionals, patients,
payers) remains to be identified. Countries with vaccin-
ating pharmacists have adopted various solutions [8].
Funding
As with all public health policies, the question of fund-
ing is vital to ensuring the sustainability of pharmacy-
based vaccine interventions. The administration of
vaccines undeniably represents an extra workload for
pharmacists, and adequate compensation should be pro-
vided to all immunizers. Some vaccines may be covered
by national health systems, while others are not, and this
may influence the choice of the vaccines that pharma-
cists are willing to provide. Ideally, reimbursement for
pharmacy immunization should be integrated into the
national health system (if one exists) in the same way as
for drugs that are dispensed there. This is a point that
needs to be negotiated in every country, region or can-
ton between relevant stakeholders, according to national
structures for public and private healthcare coverage [8].
International collaboration for advocacy
At an international level, there is a compelling need for
a joint action plan on national vaccination policies. Des-
pite the existence of European Union recommendations,
most countries organise vaccine delivery differently, and
a joint action plan at an international level would facili-
tate implementation of vaccination programmes in a
more uniform manner. Advocacy should also include
the necessity to have different pharmacy and medical so-
cieties engage in dialogue, to reach a consensus on how
to improve coverage in each country by defining their
respective roles and responsibility. Concerted collabora-
tive action at an international level to improve access to
adult vaccinations may also send a strong message to
the public, and help reduce vaccine hesitancy and
strengthen the supply of vaccines. To move towards this
goal, professional organisations need to call on govern-
ments to involve pharmacies in vaccination, and lobby
policy-makers to change legislation in this regard. They
can also have a role in providing evidence of the efficacy
of involving pharmacists in vaccine uptake; this may be
especially convincing for countries where other medical
professions who currently provide vaccination are reluc-
tant to see other professional groups “compete” to pro-
vide immunization services. By supporting calls from
within each country to improve vaccine access via phar-
macy immunizations, international professional societies
and organizations can provide additional impetus for
change. In this regard, the EICA has a key role to play in
providing support for the development of synergistic ef-
forts and helping to coordinate educative initiatives
across countries.
Conclusions
Several key messages for the pharmacy profession came
out of this stakeholder’s meeting. Firstly, it is important to
ensure that the public better understands the need for
vaccination across the lifespan, and trust-building inter-
ventions are critical to promote information acceptance.
Second, payers, namely governments, need to understand
the need, and provide the necessary resources to fund the
service. In this context, pharmacists are health profes-
sionals who have the skills, capabilities and logistic cap-
acity to vaccinate. There is a compelling need to promote
the role of pharmacists as a key part of healthcare, preven-
tion, and well-being promotion, working in concert with
other health professionals towards a common goal,
namely the care pathway to keeping patients healthy.
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